Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands.

Bill, Ruben; Deschler, Daniel G; Pittet, Mikael J; Pai, Sara I; Sadow, Peter M; Park, Jong Chul (2022). Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands. Cancer reports, 5(3), e1491. Wiley 10.1002/cnr2.1491

[img]
Preview
Text
CNR2-5-e1491.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (6MB) | Preview

BACKGROUND

Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease.

CASE

We present the case of a female patient with secretory carcinoma arising in the base of tongue with persistent disease after debulking surgery and definitive chemoradiation. As an alternative to salvage surgery, which would have resulted in significant impairment of swallowing and speech function, a targeted therapy with the TRK-inhibitor larotrectinib against an identified ETV6-NTRK3 fusion product was initiated. Larotrectinib treatment has been well tolerated, resulted in durable complete response and the patient maintains good swallowing and speech function.

CONCLUSION

The presented case underscores the importance of the accurate diagnosis of secretory carcinoma. It further highlights the impact of molecular testing as targeted therapies may play an important role in the management of advanced salivary gland cancers.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bill, Ruben

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2573-8348

Publisher:

Wiley

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

19 Sep 2022 11:38

Last Modified:

05 Dec 2022 16:24

Publisher DOI:

10.1002/cnr2.1491

PubMed ID:

34231337

Uncontrolled Keywords:

NTRK fusion head and neck cancer larotrectinib minor salivary glands secretory carcinoma

BORIS DOI:

10.48350/172996

URI:

https://boris.unibe.ch/id/eprint/172996

Actions (login required)

Edit item Edit item
Provide Feedback